Liver ergothioneine accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible mechanism of defence?

References

• Cheah IK, Halliwell B. Ergothioneine: antioxidant potential, physiological function and role in disease. Biochim Biophys Acta 2012;1822:784–793.
   PubMed Web of Science ®Google Scholar
• Akanmu D, Cecchini R, Aruoma OI, Halliwell B. The antioxidant action of ergothioneine. Arch Biochem Biophys 1991;288:10–16.
   PubMed Web of Science ®Google Scholar
• Hartman PE. Ergothioneine as antioxidant. Methods Enzymol 1990;186:310–318.
   PubMed Web of Science ®Google Scholar
• Zhu BZ, Mao L, Fan RM, Zhu JG, Zhang YN, Wang J, et al. Ergothioneine prevents copper-induced oxidative damage to DNA and protein by forming a redox-inactive ergothioneine-copper complex. Chem Res Toxicol 2011;24:30–34.
   PubMed Web of Science ®Google Scholar
• Motohash. N, Mori I, Sugiura Y, Tanaka H. Metal-complexes of ergothioneine. Chem Pharm Bull 1974;22:654–657.
   Web of Science ®Google Scholar
• Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 2005;102:5256–5261.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155–161.
   PubMed Web of Science ®Google Scholar
• Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre, PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222–226.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012;10:162–172.
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842–845.
   PubMed Web of Science ®Google Scholar
• Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol 2014;20:9038–9049.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836–1846.
   PubMed Web of Science ®Google Scholar
• Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005;28:2061–2063.
   PubMed Web of Science ®Google Scholar
• Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006;154:333–340.
   PubMed Web of Science ®Google Scholar
• Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003;35:172–178.
   PubMedGoogle Scholar
• Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931–939.
   PubMed Web of Science ®Google Scholar
• Ye P, Cheah IK, Halliwell B. High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage? Biochim Biophys Acta 2013;1832:355–364.
   PubMed Web of Science ®Google Scholar
• Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004;79:502–509.
   PubMed Web of Science ®Google Scholar
• Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol 2008;294:G27–G38.
   PubMed Web of Science ®Google Scholar
• Ye P, Cheah IK, Halliwell B. A high-fat and cholesterol diet causes fatty liver in guinea pigs. The role of iron and oxidative damage. Free Radic Res 2013;47:602–613.
   PubMed Web of Science ®Google Scholar
• Milne GL, Dai Q, Roberts LJ, 2nd. The isoprostanes-25 years later. Biochim Biophys Acta 2015;1851:433–445.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Lee, CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 2010;13:145–156.
   PubMed Web of Science ®Google Scholar
• Langford MP, Redens TB, Harris NR, Lee S, Jain SK, Reddy S, McVie R. Plasma levels of cell-free apoptotic DNA ladders and gamma-glutamyltranspeptidase (GGT) in diabetic children. Exp Biol Med (Maywood) 2007;232:1160–1169.
   PubMed Web of Science ®Google Scholar
• Szasz G. A kinetic photometric method for serum gamma-glutamyl transpeptidase. Clin Chem 1969;15:124–136.
   PubMed Web of Science ®Google Scholar
• Lee CY, Huang SH, Jenner AM, Halliwell B. Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic Biol Med 2008;44:1314–1322.
   PubMed Web of Science ®Google Scholar
• Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3 – new capabilities and interfaces. Nucleic Acids Res 2012;40:e115.
   PubMed Web of Science ®Google Scholar
• Seet RC, Quek AM, Lim EC, Halliwell B. Biomarkers of oxidative damage are elevated among individuals with high cardiovascular risk: refining subject selection strategies for antioxidant trials. Free Radic Res 2013;47:283–290.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM. Free radicals in biology and medicine. 5th ed. Oxford: Clarendon Press; 2015.
   Google Scholar
• Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, et al. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Pharm Res 2010;27:832–840.
   PubMed Web of Science ®Google Scholar
• Lacaud G, Gore L, Kennedy M, Kouskoff V, Kingsley P, Hogan C, et al. Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. Blood 2002;100:458–466.
   PubMed Web of Science ®Google Scholar
• Tokuhiro S, Yamada, R, Chang, XT, Suzuki, A, Kochi, Y, Sawada, T, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nature Genetics 2003;35:341–348.
   PubMed Web of Science ®Google Scholar
• Maeda T, Hirayama M, Kobayashi D, Miyazawa K, Tamai I. Mechanism of the regulation of organic cation/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines. Drug Metab Dispos 2007;35:394–401.
   PubMed Web of Science ®Google Scholar
• Bedirli A, Sakrak O, Muhtaroglu S, Soyuer I, Guler I, Riza Erdogan A, Sozuer EM. Ergothioneine pretreatment protects the liver from ischemia-reperfusion injury caused by increasing hepatic heat shock protein 70. J Surg Res 2004;122:96–102.
   PubMed Web of Science ®Google Scholar
• Hama T, Konishi T, Tamaki N, Tsunemori F, Okumura H. Studies on ergothioneine: (I) Distribution in the body and the subcellular fractions of liver. Vitamins 1972;46:121–126.
   Google Scholar
• Kawano H, Murata H, Iriguchi S, Mayumi T, Hama T. Studies on ergothioneine. XI. Inhibitory effect on lipid peroxide formation in mouse liver. Chem Pharm Bull (Tokyo) 1983;31:1682–1687.
   PubMed Web of Science ®Google Scholar
• Deiana M, Rosa A, Casu V, Piga R, Assunta Dessi M, Aruoma OI. L-ergothioneine modulates oxidative damage in the kidney and liver of rats in vivo: studies upon the profile of polyunsaturated fatty acids. Clin Nutr 2004;23:183–193.
   PubMed Web of Science ®Google Scholar
• Cheah IK, Ong RL, Gruber J, Yew TS, Ng LF, Chen CB, Halliwell B. Knockout of a putative ergothioneine transporter in Caenorhabditis elegans decreases lifespan and increases susceptibility to oxidative damage. Free Radic Res 2013;47:1036–1045.
   PubMed Web of Science ®Google Scholar
• Kawano H, Cho K, Haruna Y, Kawai Y, Mayumi T, Hama T. Studies on ergothioneine. X. Effects of ergothioneine on the hepatic drug metabolizing enzyme system and on experimental hepatic injury in rats. Chem Pharm Bull (Tokyo) 1983;31:1676–1681.
   PubMed Web of Science ®Google Scholar
• Yamagata T, Maki K, Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol 2005;82:1–8.
   PubMed Web of Science ®Google Scholar
• Okuda T, Nishimura M, Nakao M, Fujita Y. RUNX1/AML1: a central player in hematopoiesis. Int J Hematol 2001;74:252–257.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Aizawa S, Maeda T, Tsuboi I, Yabuuchi H, Nezu J, et al. Expression of organic cation transporter OCTN1 in hematopoietic cells during erythroid differentiation. Exp Hematol 2004;32:1156–1162.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugiura S, Kobayashi D, Yoshida K, Yabuuchi H, Aizawa S, et al. Decreased proliferation and erythroid differentiation of K562 cells by siRNA-induced depression of OCTN1 (SLC22A4) transporter gene. Pharm Res 2007;24:1628–1635.
   PubMed Web of Science ®Google Scholar
• Yang NC, Lin HC, Wu JH, Ou HC, Chai YC, Tseng CY, et al. Ergothioneine protects against neuronal injury induced by beta-amyloid in mice. Food and Chemical Toxicology 2012;50:3902–3911.
   PubMed Web of Science ®Google Scholar
• Song T-Y, Chen C-L, Liao J-W, Ou H-C, Tsai M-S. Ergothioneine protects against neuronal injury induced by cisplatin both in vitro and in vivo. Food Chem Toxicol 2010;48:3492–3499.
   PubMed Web of Science ®Google Scholar
• Li RW, Yang C, Sit AS, Kwan YW, Lee SM, Hoi MP, et al. Uptake and protective effects of ergothioneine in human endothelial cells. J Pharmacol Exp Ther 2014;350:691–700.
   PubMed Web of Science ®Google Scholar
• Arduini A, Eddy L, Hochstein P. The reduction of ferryl myoglobin by ergothioneine: a novel function for ergothioneine. Arch Biochem Biophys 1990;281:41–43.
   PubMed Web of Science ®Google Scholar
• Weigand-Heller AJ, Kris-Etherton PM, Beelman RB. The bioavailability of ergothioneine from mushrooms (Agaricus bisporus) and the acute effects on antioxidant capacity and biomarkers of inflammation. Prev Med 2012;54:S75–S78.
   PubMed Web of Science ®Google Scholar
• Sakrak O, Kerem M, Bedirli A, Pasaoglu H, Akyurek N, Ofluoglu E, Gultekin FA. Ergothioneine modulates proinflammatory cytokines and heat shock protein 70 in mesenteric ischemia and reperfusion injury. J Surg Res 2008;144:36–42.
   PubMed Web of Science ®Google Scholar
• Laurenza I, Colognato R, Migliore L, Del Prato S, Benzi L. Modulation of palmitic acid-induced cell death by ergothioneine: evidence of an anti-inflammatory action. Biofactors 2008;33:237–247.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Terada K, Oyadomari S, Inomata Y, Mori M, Gotoh T. Induction of molecular chaperones in carbon tetrachloride-treated rat liver: implications in protection against liver damage. Cell Stress Chaperones 2004;9:58–68.
   PubMed Web of Science ®Google Scholar
• Bao XQ, Liu GT. Bicyclol: a novel antihepatitis drug with hepatic heat shock protein 27/70-inducing activity and cytoprotective effects in mice. Cell Stress Chaperones 2008;13:347–355.
   PubMed Web of Science ®Google Scholar
• Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, Massie B. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000;20:7146–7159.
   PubMed Web of Science ®Google Scholar
• Doi Y, Hamazaki K, Yabuki M, Tanaka N, Utsumi K. Effect of HSP70 induced by warm ischemia to the liver on liver function after partial hepatectomy. Hepatogastroenterology 2001;48:533–540.
   PubMed Web of Science ®Google Scholar
• Kuboki S, Schuster R, Blanchard J, Pritts TA, Wong HR, Lentsch AB. Role of heat shock protein 70 in hepatic ischemia-reperfusion injury in mice. Am J Physiol Gastrointest Liver Physiol 2007;292:G1141–1149.
   Google Scholar
• Ong WY, Jenner AM, Pan N, Ong CN, Halliwell B. Elevated oxidative stress, iron accumulation around microvessels and increased 4-hydroxynonenal immunostaining in zone 1 of the liver acinus in hypercholesterolemic rabbits. Free Radic Res 2009;43:241–249.
   PubMed Web of Science ®Google Scholar
• Ferroni P, Basili S, Falco A, Davi G. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid Redox Signal 2004;6:747–756.
   PubMed Web of Science ®Google Scholar
• Busnelli M, Manzini S, Froio A, Vargiolu A, Cerrito MG, Smolenski RT, et al. Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury – rescue by high-dose statin treatment. PLoS One 2013;8:e80588.
   Google Scholar
• Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77–85.
   PubMed Web of Science ®Google Scholar
• George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311–318.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009;39:213–222.
   PubMed Web of Science ®Google Scholar
• Shim JJ. Body iron, serum ferritin, and nonalcoholic fatty liver disease. Korean J Hepatol 2012;18:105–107.
   PubMedGoogle Scholar
• Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251–1258.
   PubMed Web of Science ®Google Scholar
• Minqin R, Rajendran R, Pan N, Tan BK, Ong WY, Watt F, Halliwell B. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med 2005;38:1206–1211.
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014;20:3002–3010.
   PubMed Web of Science ®Google Scholar
• Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, et al. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 2011;300:G1094–1104.
   Google Scholar
• Hanlon DP. Interaction of ergothioneine with metal ions and metalloenzymes. J Med Chem 1971;14:1084–1087.
   PubMed Web of Science ®Google Scholar
• Pallottini V, Martini C, Pascolini A, Cavallini G, Gori Z, Bergamini E, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS. Mech Ageing Dev 2005;126:845–851.
   PubMed Web of Science ®Google Scholar
• Zhong S, Zhao L, Li Q, Yang P, Varghese Z, Moorhead JF, et al. Inflammatory stress exacerbated mesangial foam cell formation and renal injury via disrupting cellular cholesterol homeostasis. Inflammation 2015;38:959–971.
   PubMed Web of Science ®Google Scholar